ArticleMaterials today. Bio2025
Dual-functional pH-sensitive nanoliposomes modified with CD47 mimicry peptide enhance icariin delivery to attenuate neuroinflammation and oxidative stress in epilepsy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- d-Leucine modifiedRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Around 30 % of patients fail to achieve seizure-free with existing anti-seizure medications (ASMs), and developing drugs that target neuroinflammatory and oxidative stress may benefit patients with refractory epilepsy. The bioactive compound icariin (ICA) isolated from the traditional Chinese medicine Epimedium has strong anti-inflammatory and antioxidant effects. Nonetheless, the clinical application of ICA is restricted by its low bioavailability and limited ability to penetrate the blood-brain barrier (BBB). This research developed a pH-sensitive nanoliposome delivery system modified with CD47 mimicry peptide(ICA@LipD-CD47) to enhance the therapeutic efficacy of ICA for epilepsy. Through the immune escape mechanism of CD47 mimicry peptide, the phagocytosis of the drug-loaded nanoparticles by macrophages could be reduced, thereby facilitating the prolonged circulation of ICA. Additionally, considering the acidic microenvironment present in the epileptogenic foci, pH-sensitive liposomes could enhance the efficiency of ICA's targeted entry into the epileptogenic foci. In this study, network pharmacology, animal experiments, and transcriptomics analysis confirmed the effect of ICA in alleviating epilepsy-induced inflammation and oxidative stress. Moreover, ICA@LipD-CD47 demonstrated prolonged circulation and effective targeting of epileptogenic foci, significantly alleviating neuronal damage and cognitive dysfunction in epileptic mice. As a novel nano-delivery system, ICA@LipD-CD47 presents a promising approach to improve the therapeutic effectiveness of ICA for treating epilepsy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.